1. Prognostic potential of standard laboratory parameters in patients with metastatic renal cell cancer receiving first-line immunotherapy
- Author
-
Bjoern Thorben Buerk, Cathrin Kusiek, Vayda Schüttke, Marcus Sondermann, Abdulbaki Yakac, Elena Abbate, Susanne Fuessel, Christian Thomas, and Kati Erdmann
- Subjects
Early kinetics ,γ-Glutamyltransferase ,Immune checkpoint inhibitors ,Lactate dehydrogenase ,Prognostic biomarkers ,Metastatic renal cell cancer ,Medicine ,Science - Abstract
Abstract Through their involvement in cancer metabolism, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), γ-glutamyltransferase (GGT) and lactate dehydrogenase (LDH) reflect the tumor burden and thus could have a prognostic potential for patients treated with immune checkpoint inhibitors (CPI). Therefore, this study investigated the prognostic potential of these parameters in a real-world cohort of patients with metastatic renal cell cancer (mRCC) under first-line CPI-based therapy. The retrospective study cohort included 82 mRCC patients treated with CPI-based first-line therapy between 2019 and 2023. Progression-free survival (PFS), overall survival (OS) and response rates were evaluated according to baseline levels and early dynamic changes of ALAT, ASAT, GGT and LDH. Multivariate Cox proportional hazard regression models were generated to identify independent prognosticators for PFS and OS. High baseline levels and non-normalized kinetics of ALAT, ASAT, GGT and LDH were significantly associated with shorter PFS and OS (p
- Published
- 2024
- Full Text
- View/download PDF